SGEN - Seattle Genetics, Inc.
| Previous Close | 66.42 |
| Open | 65.81 |
| Bid | 21.09 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 64.02 - 66.00 |
| 52 Week Range | 50.71 - 84.37 |
| Volume | 431,080 |
| Avg. Volume | 815,987 |
| Market Cap | 10.385B |
| Beta (3Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.46 |
- Business Wire•5 days ago
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3rd
- Simply Wall St.•6 days ago
Seattle Genetics, Inc. (NASDAQ:SGEN): Financial Strength Analysis
With a market capitalization of US$11b, Seattle Genetics, Inc. (NASDAQ:SGEN) is a large-cap stock, which is considered...
- Business Wire•6 days ago
Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference
Seattle Genetics, Inc. announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m.
- Markit•14 days ago
See what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on April 29. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.77 billion over the last one-month into ETFs that hold SGEN are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•18 days ago
Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada
-Health Canada Approves ADCETRIS in Combination with AVD Chemotherapy for the Treatment of Previously Untreated Hodgkin Lymphoma Based on Positive Phase 3 ECHELON-1 Clinical Trial
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of SGEN earnings conference call or presentation 25-Apr-19 8:30pm GMT
Q1 2019 Seattle Genetics Inc Earnings Call
- Investopedia•20 days ago
Top Biotech Stocks for February 2019
Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.
- Motley Fool•21 days ago
Seattle Genetics' "Growth Is Tracking Well"
The biotech is on track to hit its 2019 revenue guidance for Adceris sales to increase 28% to 34%.
- Zacks•25 days ago
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Motley Fool•25 days agoSEATTLE GENETICS INC (SGEN) Q1 2019 Earnings Call Transcript
SGEN earnings call for the period ending March 31, 2019.
- Benzinga•25 days ago
The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
- Associated Press•26 days ago
Seattle Genetics: 1Q Earnings Snapshot
On a per-share basis, the Bothell, Washington-based company said it had a loss of 8 cents. Losses, adjusted for investment gains, came to 32 cents per share. The results beat Wall Street expectations. ...
- Business Wire•26 days ago
Seattle Genetics Reports First Quarter 2019 Financial Results
-ADCETRIS® Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42 Percent Over the First Quarter of 2018-
- Benzinga•26 days ago
The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...
- ACCESSWIRE•26 days ago
Seattle Genetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Seattle Genetics, Inc. (NASDAQ: SGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 4:30 PM ...
- Insider Monkey•last month
Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)?
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
- Zacks•last month
Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•last month
Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. To wit, the Seattle Genetics, Inc. (NASDAQ:SGEN...
- Zacks•last month
Seattle Genetics' Adcetris Progresses Well Amid Competition
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
- GuruFocus.com•last month
5 Oncology Companies That Are Set to Run
The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.
- Zacks•last month
Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Business Wire•2 months ago
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019
Seattle Genetics, Inc. announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
- Zacks•2 months ago
Seattle Genetics Closes Enrollment in Cervical Cancer Study
Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.
- Zacks•2 months ago
Seattle Genetics, Astellas Report Positive Cancer Study Data
Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.
